Profile picture

Professor Perry Mark Elliott

University College London, London (United Kingdom of Great Britain & Northern Ireland)
Membership: FESC Member
Follow
Biography
Perry Elliott) is Professor of Cardiovascular Medicine and director of the Centre for Heart Muscle Disease at University College London (UCL) and a consultant cardiologist in the Centre for Inherited Cardiovascular Disease at St. Bartholomew's Hospital London, UK. He is Chairman of the ESC Heart Academy and the ESC Council on Cardiovascular Genomics. He is past Chairman of the ESC Working Group on Myocardial and Pericardial Diseases (2010–2012), the Executive Committee for the European Outcomes Research Programme (EORP) registry on cardiomyopathies and the ESC Guideline Task Force on Hypertrophic Cardiomyopathy. He is President of Cardiomyopathy UK, Europe’s foremost charity for patients with heart muscle disease. Over the past 25 years, Prof. Elliott has established an international reputation in the field of heart muscle disease, authoring more than 500 peer-reviewed papers on the subject. He develops diagnostic standards, risk stratification tools and clinical service models.
Logo ESC

Contributor content

Sudden cardiac death risk prediction: guidance for everyday practice
Session
Sudden cardiac death risk prediction: guidance for everyday practice
12 April 2026
Day in Focus by ESC TV Today - Sunday 31 August 2025
Session
Day in Focus by ESC TV Today - Sunday 31 August 2025
31 August 2025
Late-Breaking Clinical Science: spectrum of cardiomyopathies
Session
Late-Breaking Clinical Science: spectrum of cardiomyopathies
31 August 2025
Cardiology Toolbox - Genetics for cardiologists
Session
Cardiology Toolbox - Genetics for cardiologists
29 August 2025
Young Investigator Award Session in Heart Failure and Cardiomyopathies
Session
Young Investigator Award Session in Heart Failure and Cardiomyopathies
29 August 2025
Trial updates and other studies in hypertrophic cardiomyopathy and aortic stenosis
Session
Trial updates and other studies in hypertrophic cardiomyopathy and aortic stenosis
1 September 2024
Day in Focus - Sunday 1 September
Session
Day in Focus - Sunday 1 September
1 September 2024
New treatment targets for personalised therapy in genetic cardiomyopathies
Session
New treatment targets for personalised therapy in genetic cardiomyopathies
1 September 2024
Managing hypertrophic cardiomyopathy (HCM) in clinical practice: the patient journey
Session
Managing hypertrophic cardiomyopathy (HCM) in clinical practice: the patient journey
31 August 2024
Leveraging data: the patient path to optimal outcomes in ATTR cardiomyopathy
Session
Leveraging data: the patient path to optimal outcomes in ATTR cardiomyopathy
31 August 2024

ESC 365 is supported by